Please select the option that best describes you:
Do you think there will be a role for duvelisib in the treatment of relapsed/refractory chronic lymphocytic leukemia?
Specifically, in patients that had progression or developed toxicity on ibrutinib? Idelalisib is very toxic and venetoclax a labor-intensive drug to get started especially in our very old patients.
Answer from: Medical Oncologist at Academic Institution
I believe this agent could find a home for therapy in CLL as it is given by itself provided that further efficacy is demonstrated in a population where it would be most likely used, ibrutinib resistant CLL. Additionally, incorporation into non-BTK inhibitor combinations would also be pos...
Sign in or Register to read more